ATE197667T1 - Angiogenesehemmung mit synthetischen matrix- metalloproteaseinhibitoren - Google Patents

Angiogenesehemmung mit synthetischen matrix- metalloproteaseinhibitoren

Info

Publication number
ATE197667T1
ATE197667T1 AT93902938T AT93902938T ATE197667T1 AT E197667 T1 ATE197667 T1 AT E197667T1 AT 93902938 T AT93902938 T AT 93902938T AT 93902938 T AT93902938 T AT 93902938T AT E197667 T1 ATE197667 T1 AT E197667T1
Authority
AT
Austria
Prior art keywords
matrix metalloprotease
metalloprotease inhibitors
angiogenesis inhibition
synthetic matrix
controlling
Prior art date
Application number
AT93902938T
Other languages
English (en)
Inventor
Richard E Galardy
Original Assignee
Glycomed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycomed Inc filed Critical Glycomed Inc
Application granted granted Critical
Publication of ATE197667T1 publication Critical patent/ATE197667T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT93902938T 1992-01-07 1993-01-04 Angiogenesehemmung mit synthetischen matrix- metalloproteaseinhibitoren ATE197667T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/817,039 US5268384A (en) 1990-11-21 1992-01-07 Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors
PCT/US1993/000054 WO1993013741A2 (en) 1992-01-07 1993-01-04 Inhibition of angiogenesis by synthetic matrix metalloprotease inhibitors

Publications (1)

Publication Number Publication Date
ATE197667T1 true ATE197667T1 (de) 2000-12-15

Family

ID=25222227

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93902938T ATE197667T1 (de) 1992-01-07 1993-01-04 Angiogenesehemmung mit synthetischen matrix- metalloproteaseinhibitoren

Country Status (7)

Country Link
US (2) US5268384A (de)
EP (1) EP0663823B1 (de)
JP (1) JPH07503007A (de)
AT (1) ATE197667T1 (de)
AU (1) AU3433293A (de)
DE (1) DE69329699D1 (de)
WO (1) WO1993013741A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
US5853746A (en) * 1991-01-31 1998-12-29 Robert Francis Shaw Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier
US5756825A (en) * 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
CA2160139A1 (en) * 1993-04-07 1994-10-13 Richard Edward Galardy Synthetic matrix metalloprotease inhibitors and uses thereof
CA2472404A1 (en) 1993-07-19 1995-02-02 Angiotech Pharmaceuticals, Inc. Combination of stent and anti-angiogenic factor
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US6037472A (en) * 1993-11-04 2000-03-14 Syntex (U.S.A.) Inc. Matrix metalloprotease inhibitors
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
US5831004A (en) * 1994-10-27 1998-11-03 Affymax Technologies N.V. Inhibitors of metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5840698A (en) * 1994-10-27 1998-11-24 Affymax Technologies N.V. Inhibitors of collagenase-1 and stormelysin-I metalloproteases, pharmaceutical compositions comprising same and methods of their use
US5532265A (en) * 1994-11-30 1996-07-02 The Board Of Trustees Of The Leland Stanford Junior University Treatment of central nervous system inflammatory disease with matrix metalloprotease inhibitors
US5563130A (en) * 1994-12-13 1996-10-08 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5567693A (en) * 1994-12-13 1996-10-22 American Cyanamid Company Method for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5574026A (en) * 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
US5843925A (en) * 1994-12-13 1998-12-01 American Cyanamid Company Methods for inhibiting angiogenesis, proliferation of endothelial or tumor cells and tumor growth
US5843920A (en) * 1996-09-16 1998-12-01 Biocell Technology, Llc Anionic saccharides for extraction of anti-angiogenic protein from cartilage
US6281245B1 (en) 1996-10-28 2001-08-28 Versicor, Inc. Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
AU5426398A (en) 1996-10-28 1998-05-22 Versicor Inc Methods for solid-phase synthesis of hydroxylamine compounds and derivatives, and combinatorial libraries thereof
US20050191661A1 (en) * 1996-11-06 2005-09-01 Tetsuya Gatanaga Treatment of inflammatory disease by cleaving TNF receptors
JP2001508648A (ja) 1996-11-06 2001-07-03 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 腫瘍壊死因子レセプター放出酵素、酵素を含む組成物、およびその使用方法
US6593456B1 (en) * 1996-11-06 2003-07-15 The Regents Of The University Of California Tumor necrosis factor receptor releasing enzyme
WO1999041232A1 (en) * 1998-02-13 1999-08-19 British Biotech Pharmaceuticals Limited Cytostatic agents
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6794518B1 (en) * 1998-12-18 2004-09-21 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6673843B2 (en) * 1999-06-30 2004-01-06 Emory University Curcumin and curcuminoid inhibition of angiogenesis
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
AU7311501A (en) 2000-06-29 2002-03-22 Quick Med Technologies Inc Cosmetic composition and method
US20040185127A1 (en) * 2001-06-29 2004-09-23 Lerner David S. Cosmetic composition and method
US6436629B1 (en) * 2000-10-27 2002-08-20 The Regents Of The University Of California Modulating angiogenesis
US6632835B2 (en) 2001-02-22 2003-10-14 Nanodesign Inc. Dibenzo[c]chromen-6-one derivatives as anti-cancer agents
AR036053A1 (es) * 2001-06-15 2004-08-04 Versicor Inc Compuestos de n-formil-hidroxilamina, un proceso para su preparacion y composiciones farmaceuticas
EP1406893B1 (de) * 2001-06-15 2007-04-18 Vicuron Pharmaceuticals, Inc. Bicyclische pyrrolidinverbindungen
IL161057A0 (en) * 2001-09-25 2004-08-31 Quick Med Technologies Inc Composition and method for minimizing or avoiding adverse effects of vesicants
EP1572078A4 (de) * 2002-03-08 2006-08-09 Univ Emory NEUE CURCUMINOID-FAKTOR-VIIa-KONSTRUKTE ALS MITTEL ZUR UNTERDRÜCKUNG VON TUMORWACHSTUM UND ANGIOGENESE
US20080139512A1 (en) * 2002-09-25 2008-06-12 Quick-Med Technologies, Inc. Method for minimizing or avoiding adverse effects of vesicants
AU2003300076C1 (en) 2002-12-30 2010-03-04 Angiotech International Ag Drug delivery from rapid gelling polymer composition
TWI476206B (zh) * 2003-07-18 2015-03-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
EP2287326A1 (de) 2003-08-08 2011-02-23 Arriva Pharmaceuticals, Inc. Verfahren zur Protein-Produktion in Hefe
ATE530165T1 (de) * 2003-11-14 2011-11-15 Baxter Int Alpha1-antitrypsin-zusammensetzungen und behandlungsverfahren unter verwendung dieser zusammensetzungen
EP1737499A4 (de) 2004-03-09 2009-07-22 Arriva Pharmaceuticals Inc Behandlung von chronisch obstruktiver lungenerkrankung durch inhalation von niedrigen dosen eines proteasehemmers
US20070105768A1 (en) * 2004-11-10 2007-05-10 Rajiv Nayar Dry recombinant human alpha 1-antitrypsin formulation
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
US8435541B2 (en) 2010-09-02 2013-05-07 Bath & Body Works Brand Management, Inc. Topical compositions for inhibiting matrix metalloproteases and providing antioxidative activities
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN114213414A (zh) * 2022-01-24 2022-03-22 山东安信制药有限公司 一种他达拉非制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4291048A (en) * 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
JPS5758626A (en) * 1980-09-26 1982-04-08 Rikagaku Kenkyusho Carcinostatic agent
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
US4558034A (en) * 1984-01-31 1985-12-10 The Board Of Trustees Of The University Of Kentucky Inhibitors of bacterial collagenase
DE3482590D1 (de) * 1984-04-12 1990-08-02 Searle & Co Carboxyalkyl-peptid-derivate.
US4698342A (en) * 1985-07-16 1987-10-06 Serotonin Industries Of Charleston Method and compositions for controlling pain, depression and sedation
US4743587A (en) * 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4599361A (en) * 1985-09-10 1986-07-08 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
US4681894A (en) * 1986-09-26 1987-07-21 Ortho Pharmaceutical Corporation Hydroxamic acids and esters
ZW23187A1 (en) * 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
ATE106087T1 (de) * 1987-03-17 1994-06-15 Res Corp Technologies Inc Synthetische inhibitoren von säugetier- collagenase.
US4943587A (en) * 1988-05-19 1990-07-24 Warner-Lambert Company Hydroxamate derivatives of selected nonsteroidal antiinflammatory acyl residues and their use for cyclooxygenase and 5-lipoxygenase inhibition
GB8827308D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
JPH03109324A (ja) * 1989-09-22 1991-05-09 Microbial Chem Res Found 血管新生阻害剤
DK0512071T3 (da) * 1990-01-25 1996-11-25 Childrens Hospital Fremgangsmåde og sammensætninger til inhibering af angiogenese
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5239078A (en) * 1990-11-21 1993-08-24 Glycomed Incorporated Matrix metalloprotease inhibitors
US5114953A (en) * 1990-11-21 1992-05-19 University Of Florida Treatment for tissue ulceration
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
ES2069833T3 (es) * 1990-12-03 1995-05-16 Celltech Ltd Derivados peptidilicos.

Also Published As

Publication number Publication date
AU3433293A (en) 1993-08-03
EP0663823B1 (de) 2000-11-22
WO1993013741A3 (en) 1993-08-19
WO1993013741A2 (en) 1993-07-22
JPH07503007A (ja) 1995-03-30
EP0663823A4 (de) 1997-06-04
US5268384A (en) 1993-12-07
US5696147A (en) 1997-12-09
EP0663823A1 (de) 1995-07-26
DE69329699D1 (de) 2000-12-28

Similar Documents

Publication Publication Date Title
ATE197667T1 (de) Angiogenesehemmung mit synthetischen matrix- metalloproteaseinhibitoren
GR3035730T3 (en) Inhibitors of dipeptidyl-aminopeptidase type iv.
DE3689553D1 (de) Flaches Magnetron-Zerstäubungsgerät und dessen Magnetfeldquelle.
EP1002556A3 (de) Verwendung von MMP Hemmer
DE69621021D1 (de) Inhibitoren der plättchenaggregation
DK0572166T3 (da) Hidtil ukendte 7beta-substitueret-4-aza-5beta-androstan-3-oner som 5beta-reduktaseinhibitorer
DE69302872D1 (de) Leistungversorgung mit Verbesserung des Leistungsfaktors
DE3866938D1 (de) Steroid-5-alpha-reduktase-inhibitoren.
FI933277A7 (fi) Amiinidioli proteaasi-inhibiittorit
FI932249L (fi) Dubbelverkande inhibitorer
FI850041A0 (fi) Anordning foer uppbevaring och lagring av artiklar.
NL930005I2 (nl) 17 Beta-gesubstitueerde-4-aza-5alfa-androstenonen en gebruik ervan als inhibitoren van 5alfa-reduct ase.
DE59301599D1 (de) Magnetventil
NO924882D0 (no) Slipeplate
DE69333909D1 (de) Leseverstärker mit lokalen Schreibtreibern
DE69227392D1 (de) Serumfreies Medium zur Züchtung von Tierzellen
NO944406D0 (no) Nye 7 se inhibitorer
MY104021A (en) Benzamide protease inhibitors.
DK0653092T3 (da) Materialesystem til magneto-optisk optagelse
DE69316741D1 (de) Magnetventil
FI921390A7 (fi) Friktionsfast staol
GB2257159B (en) Low-permeability high-strength target material for the formation of thin magnetooptical recording films
DK491988A (da) Modificerede plasminogen-aktivatorer
DE69625910D1 (de) Penamsulfone als beta-laktamase inhibitoren
DE69401967D1 (de) Abspaltbare Hydroxycarbonsäuren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties